ZA963735B - High-dose chromic picolinate treatment of type ii diabetes - Google Patents

High-dose chromic picolinate treatment of type ii diabetes

Info

Publication number
ZA963735B
ZA963735B ZA963735A ZA963735A ZA963735B ZA 963735 B ZA963735 B ZA 963735B ZA 963735 A ZA963735 A ZA 963735A ZA 963735 A ZA963735 A ZA 963735A ZA 963735 B ZA963735 B ZA 963735B
Authority
ZA
South Africa
Prior art keywords
diabetes
dose
type
chromic picolinate
treatment
Prior art date
Application number
ZA963735A
Other languages
English (en)
Inventor
Mark F Mccarty
Original Assignee
Nutrition 21
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 filed Critical Nutrition 21
Publication of ZA963735B publication Critical patent/ZA963735B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA963735A 1995-05-12 1996-05-10 High-dose chromic picolinate treatment of type ii diabetes ZA963735B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/440,362 US6329361B1 (en) 1995-05-12 1995-05-12 High-dose chromic picolinate treatment of type II diabetes

Publications (1)

Publication Number Publication Date
ZA963735B true ZA963735B (en) 1997-01-09

Family

ID=23748461

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA963735A ZA963735B (en) 1995-05-12 1996-05-10 High-dose chromic picolinate treatment of type ii diabetes

Country Status (15)

Country Link
US (1) US6329361B1 (pt)
EP (1) EP0825861B1 (pt)
JP (1) JP3699124B2 (pt)
AR (1) AR004486A1 (pt)
AT (1) ATE227127T1 (pt)
AU (1) AU5733796A (pt)
BR (1) BR9608835A (pt)
DE (1) DE69624699T2 (pt)
DK (1) DK0825861T3 (pt)
ES (1) ES2183952T3 (pt)
IL (1) IL118222A (pt)
PT (1) PT825861E (pt)
RU (1) RU2195934C2 (pt)
WO (1) WO1996035421A1 (pt)
ZA (1) ZA963735B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962030A (en) 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
IL134163A0 (en) * 1997-08-08 2001-04-30 Nutrition 21 Chromium/biotin treatment of type ii diabetes
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
EP0925790A1 (en) * 1997-12-17 1999-06-30 Kartar Dr. Lalvani Vitamin and mineral combinations for the treatment of syndrome X and non-insulin dependent diabetes (NIDDM)
US5932258A (en) * 1998-04-06 1999-08-03 The Iams Company Composition and process for improving glucose metabolism in companion animals
US5948772A (en) * 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US6143301A (en) 1998-08-28 2000-11-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US5905075A (en) * 1998-08-28 1999-05-18 Ambi Inc. Chromium nicotinate compositions and uses thereof
AU6044699A (en) 1998-09-17 2000-04-03 Akesis Pharmaceuticals, Inc. Compositions and methods for treatment of glucose metabolism disorders
US6376549B1 (en) 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
ES2223924T3 (es) 2000-09-21 2005-03-01 Nutrition 21, Inc. Composiciones que contienen cromo para el tratamiento de la diabetes, la reduccion de la grasa corporal, la mejora de la sensibilidad a la insulina, la reduccion de la hiperglicemia y la reduccion de la hipercolesteremia.
WO2003090671A2 (en) * 2002-04-23 2003-11-06 Nutrition 21, Inc. Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
CN100457122C (zh) * 2002-05-14 2009-02-04 尼普洛株式会社 包含三价铬离子的化合物在制备用于预防和/或治疗淀粉样变性的药物的应用
US6831077B2 (en) * 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
US20050019435A1 (en) * 2003-07-21 2005-01-27 Jeffrey Young Method of treating non-insulin dependent diabetes mellitus and related complications
US20050085454A1 (en) * 2003-10-16 2005-04-21 Natreon Inc. Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance
CA2931881C (en) * 2007-01-31 2018-12-11 Nutrition 21, Inc. Use of chromium histidinate for treatment of cardiometabolic disorders
EP3050568B1 (en) 2007-03-13 2020-12-02 JDS Therapeutics, LLC Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
PL2448412T3 (pl) 2009-07-01 2019-11-29 Jds Therapeutics Llc Kompleksy chromu jako środki podnoszące poziom transporterów glukozy w mózgu
US8933022B2 (en) 2011-03-01 2015-01-13 Jds Therapeutics, Llc Methods and compositions for the treatment and prevention Hypoglycemia and related disorders
EP3256004A1 (en) 2015-02-13 2017-12-20 Mars, Incorporated Pet food feeding system
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.
US10820617B1 (en) 2018-03-29 2020-11-03 Government Of The United States, As Represented By The Secretary Of The Air Force All inclusive electrolytes, vitamins, and protein powder training supplement

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315927A (en) * 1980-08-08 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Dietary supplementation with essential metal picolinates
US5087623A (en) * 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US5164384A (en) 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula

Also Published As

Publication number Publication date
MX9708628A (es) 1998-06-28
IL118222A (en) 2000-06-01
US6329361B1 (en) 2001-12-11
ATE227127T1 (de) 2002-11-15
AR004486A1 (es) 1998-12-16
JP3699124B2 (ja) 2005-09-28
WO1996035421A1 (en) 1996-11-14
DK0825861T3 (da) 2003-03-03
DE69624699D1 (de) 2002-12-12
EP0825861A1 (en) 1998-03-04
AU5733796A (en) 1996-11-29
BR9608835A (pt) 1999-12-07
RU2195934C2 (ru) 2003-01-10
JPH11504941A (ja) 1999-05-11
ES2183952T3 (es) 2003-04-01
DE69624699T2 (de) 2003-03-20
IL118222A0 (en) 1996-09-12
EP0825861B1 (en) 2002-11-06
PT825861E (pt) 2003-03-31

Similar Documents

Publication Publication Date Title
ZA963735B (en) High-dose chromic picolinate treatment of type ii diabetes
GB2298440B (en) Well treatment
PL324284A1 (en) Methods of treating diabetes
ZA96740B (en) Skin treatment composition
HU9603369D0 (en) Treatment of vegetables
AU7772794A (en) Treatment of obesity
GB9519033D0 (en) Treatment
AU7166896A (en) Cancer treatment
AU7484596A (en) Combination therapy for the treatment of diabetes and obesity
AU5718396A (en) Wastewater treatment
GB2303303B (en) Medical treatment
GB9521725D0 (en) Medical treatment
GB9602162D0 (en) Treatment of waste
AUPN221195A0 (en) Combined waste treatment
AU6829696A (en) Treatment of solutions
ZA947333B (en) Treatment of titaniferous material.
GB9526264D0 (en) Medical treatment
GB2304046B (en) Diabetes therapy
GB2307858B (en) Medical treatment
ZA961060B (en) Treatment of titanium-containing material
GB9503201D0 (en) Anti-smoking treatment,therapy and illness prevention
GB9608631D0 (en) Medical treatment
GB9510065D0 (en) Treatment
AU3450995A (en) Effluent treatment
AUPN323395A0 (en) Effluent treatment